CASI Pharmaceuticals, Inc. (CASIF) stock
CASIFOTCPharmaceutical PreparationsFiscal year ends December 31
$0.10+0.00 (0.00%)
Close on Oct 19, 2026Market cap –P/E –Yield –
Earnings
CASI Pharmaceuticals's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Next report
–
Not yet scheduled
Revenue, Q4 FY2023
$6.90M
EPS, Q4 FY2023
–
Latest guidance
None
No outlook given in releases
Quarterly results
Revenue and earnings per share from each of CASI Pharmaceuticals's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Source |
|---|---|---|---|---|---|
| Q4 FY2023ended Dec 31, 2023 | Mar 28, 2024during market hours | $6.90M | – | – | Release |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Guidance
CASI Pharmaceuticals has not given guidance in its releases
Many companies give their outlook only on the conference call or not at all. When CASI Pharmaceuticals puts a forecast in an earnings release, it is listed here with the exact sentence.
Press releases
Releases CASI Pharmaceuticals filed with the SEC as exhibits to Form 8-K or 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
- 6-K
See a number that looks wrong?